GLP-1 RAs and Prior Major Adverse Limb Events in Patients With DiabetesGLP-1 RAs and Prior Major Adverse Limb Events in Patients With Diabetes
This cohort study analyzes associations of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with risk of recurrent major adverse limb events in patients with diabetes. This cohort study analyzes associations of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with risk of recurrent major adverse limb events in patients with diabetes.
Medicaid Expansion Linked to Lower Mortality in Breast CancerMedicaid Expansion Linked to Lower Mortality in Breast Cancer
(MedPage Today) — Medicaid expansion under the Affordable Care Act (ACA) was associated with lower overall mortality among women with breast cancer, according to a retrospective cohort study.
Among over 1.5 million women ages 40 to 64, Medicaid…
New therapeutic target for breast cancer involves double-stranded RNA-binding proteinsNew therapeutic target for breast cancer involves double-stranded RNA-binding proteins
A Purdue University team has discovered a new therapeutic target for triple-negative breast cancer. The research, led by Kyle Cottrell, an assistant professor of biochemistry, spotlights double-stranded ribonucleic acid (dsRNA)-binding proteins.
Tirzepatide Safety Warning; Nurse Charged Over Fake GLP-1s; Revised Afrezza DosingTirzepatide Safety Warning; Nurse Charged Over Fake GLP-1s; Revised Afrezza Dosing
(MedPage Today) — Tirzepatide (Mounjaro, Zepbound) users should never share KwikPens due to risk for transmission of blood-borne pathogens, the FDA warned in an updated label. GLP-1 medications for weight loss accounted for more than 7% of all… (MedPage Today) — Tirzepatide (Mounjaro, Zepbound) users should never share KwikPens due to risk for transmission Read More
Oral semaglutide reshapes everyday obesity visitsOral semaglutide reshapes everyday obesity visits
1. Oral semaglutide adds a pill-based option for chronic obesity care without changing the core GLP-1 tradeoffs in efficacy and gastrointestinal tolerability. 2. Clinicians will need to help patients understand that daily dosing, titration, and safety monitoring remain essential even when the formulation feels more convenient. The emergence of an oral GLP-1 option for chronic Read More
STAT+: New startup to develop a GLP-1 drug for addictionSTAT+: New startup to develop a GLP-1 drug for addiction
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. A new startup focused on GLP-1 drugs launched today, but unlike the dozens of other GLP-1 companies, this one isn’t studying weight loss. The need-to-know this morning Roche plans to launch Phase Read More
GLP-1 drugs don’t work for everyone. But personalized obesity care in the future mightGLP-1 drugs don’t work for everyone. But personalized obesity care in the future might
As doctors learn why GLP-1s don’t work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the way cancer is treated now. (Image credit: Tatsiana Volkava) As doctors learn why GLP-1s don’t work for about 50% of Read More
Large quantity of Mounjaro stolen from companyLarge quantity of Mounjaro stolen from company
The weight loss drug is taken by thieves from Phoenix Healthcare Distribution in St Albans. The weight loss drug is taken by thieves from Phoenix Healthcare Distribution in St Albans.
Medicaid Expansion and Breast Cancer MortalityMedicaid Expansion and Breast Cancer Mortality
This cohort study of more than 1.5 million women in the National Cancer Database evaluates the association between Medicaid expansion and overall mortality among women with breast cancer and assesses whether survival differs by demographic characteristics.
Medicaid Expansion and Breast Cancer Care and OutcomesMedicaid Expansion and Breast Cancer Care and Outcomes
Health Policy